Amylyx prices 17.1M-share public offering at $3.50/sh for ~$56.9M net proceeds

Amylyx Pharmaceuticals, Inc.

Offering of 17,142,857 common shares at $3.50 per share, with 30-day option for up to 2,571,428 additional shares.
Net proceeds expected to be ~$56.9 million ($65.5 million if over-allotment exercised in full).
Closing expected January 13, 2025; proceeds to fund commercialization prep, pipeline, working capital.
Underwriting agreement includes customary representations, warranties, and market standoff provisions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.